Valproic acid와 Carbapenem계 항생제 병용 투여로 인한 Valproic acid의 약동학적 변화 및 경련 발생에 대한 고찰
The effect of Valproic acid - Carbapenem antibiotics Interaction on Pharmacokinetics of Valproic acid and Seizure Development
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Valproic acid is widely used in the treatment of generalized tonic-clonic and partial seizures. The carbapenem class is the most potent and widest spectrum of antimicrobial activity. Concomitant administration of carbapenems and valproic acid has been reported to decrease the serum concentration of valproic acid, which is sometimes associated with seizures. The purpose of this study is to evaluate the changes in valproic acid concentration and half life and the frequency of seizure during concomitant administration of valproic acid and carbapenems. Method: This study was performed retrospectively on total 40 cases with identified valproic acid concentration during concomitant administration of valproic acid and carbapenems at Kangbuk Samsung Hospital from February 1st, 2006 to October 31st, 2011. Patients were classified into 3 groups: ertapenem group (n=14), imipenem group (n=12), meropenem group (n=14). Results: The mean serum concentrations in each group during combined treatment were 9.50±8.84, 21.88±8.17and 10.62±8.67 mg/L, respectively (p < 0.001). The mean half-lives in each group during concurrent use of valproic acid and carbapenems were 3.18±0.81, 4.63±1.97 and 2.67±1.69 hr, respectively (p < 0.001). The valproic acid serum concentration decreased by 75.5%, 54.1% and 84.1% and the half-life of valporoic acid decreased by 65.6%, 35.7% and 73.5%, respectively. Total cases with seizure were 12(30%) with 5(35.7%) in the ertapenem group, 3 (25.0%) in the imipenem group and 4(28.6%) in the meropenem group (p=0.911). There were no specific factors to influence on seizure development during combined treatment. Conclusion: Concurrent use of carbapenems and valproic acid should be avoided. If concomitant administration is essential, very close serum concentration monitoring and clinical observation are necessary.
Abstract
Background: Valproic acid is widely used in the treatment of generalized tonic-clonic and partial seizures. The carbapenem class is the most potent and widest spectrum of antimicrobial activity. Concomitant administration of carbapenems and valproic acid has been reported to decrease the serum concentration of valproic acid, which is sometimes associated with seizures. The purpose of this study is to evaluate the changes in valproic acid concentration and half life and the frequency of seizure during concomitant administration of valproic acid and carbapenems. Method: This study was performed retrospectively on total 40 cases with identified valproic acid concentration during concomitant administration of valproic acid and carbapenems at Kangbuk Samsung Hospital from February 1st, 2006 to October 31st, 2011. Patients were classified into 3 groups: ertapenem group (n=14), imipenem group (n=12), meropenem group (n=14). Results: The mean serum concentrations in each group during combined treatment were 9.50±8.84, 21.88±8.17and 10.62±8.67 mg/L, respectively (p < 0.001). The mean half-lives in each group during concurrent use of valproic acid and carbapenems were 3.18±0.81, 4.63±1.97 and 2.67±1.69 hr, respectively (p < 0.001). The valproic acid serum concentration decreased by 75.5%, 54.1% and 84.1% and the half-life of valporoic acid decreased by 65.6%, 35.7% and 73.5%, respectively. Total cases with seizure were 12(30%) with 5(35.7%) in the ertapenem group, 3 (25.0%) in the imipenem group and 4(28.6%) in the meropenem group (p=0.911). There were no specific factors to influence on seizure development during combined treatment. Conclusion: Concurrent use of carbapenems and valproic acid should be avoided. If concomitant administration is essential, very close serum concentration monitoring and clinical observation are necessary.
참고문헌 (16)
- 이명구, "지방대학병원 사례평가: 국내 입원환자에 있어 Carbapenem계 약물사용 평가", 한국임상약학회지, 17(2), pp.109~116 (2007), 한국임상약학회
- Nagai K, "Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem", betamipron, 1997, pp.39(2), 295~296
- 이상국, "Carbapenem계 항생제에 의한 Valproic Acid 혈중 농도 감소 7예 보고", Annals of Laboratory Medicine, 27(5), pp.338~343 (2007), 대한진단검사의학회
- Coves-Orts FJ, "Acute seizures due to a probable interaction between valproic acid and meropenem", Ann Pharmacother, 39(3), pp.533~537 (2005)
- Spriet I, "Interaction between valproate and meropenem: a retrospective study", Ann Pharmacother, 41(7), pp.1130~1136 (2007)
- Liao FF, "Decrease in serum valproic acid levels during treatment with ertapenem", Am J Health Syst Pharm, 67(15), pp.1260~1264 (2010)
- Lunde JL, "Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy", Pharmacotherapy, 27(8), pp.1202~1205 (2007)
- Hellwig TR, "Potential interaction between valproic acid and doripenem", Curr Drug Saf, 6(1), pp.54~58 (2011)
- 이영숙, "건강보험심사청구 자료에 근거한 병용금기 약물의 후향적 약물사용평가 : 처방전 조제 형태별 분석", 한국임상약학회지, 21(3), pp.249~255 (2011), 한국임상약학회
- 윤소정, "병용금기 SCREENING 프로그램 시행 후의 처방 분석", 병원약사회지, 22(3), pp.1~7 (2005), 한국병원약사회
- VillemureJ, "Epilepsy in patients with central nervous system tumors", Curr Opin Neurol, 9, pp.424~428 (1996)
- Van Breemen MSM, "Optimal seizure management in brain tumor patients", Curr Neurol Nerosci Rep, 5, pp.207~213 (2005)
- Isaac E. Silverman, "Poststroke Seizures", Arch Neurol, 59, pp.195~201 (2002)
- Hauser W, "Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935- 1984", Epilepsia, 34, pp.453~468 (1993)
- Bladin C, "Seizures after stroke: a prospective multicenter study", Arch Neurol, 57, pp.1617~1622 (2000)
- Delanty N, "Medical causes of seizures", Lancet, 352(9125), pp.383~390 (1998)